294 related articles for article (PubMed ID: 36308926)
1. Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer：A multicenter study.
Li B; Li F; Liu Z; Xu F; Ye G; Li W; Zhang Y; Zhu T; Shao L; Chen C; Sun C; Qiu B; Bu H; Wang K; Tian J
Breast; 2022 Dec; 66():183-190. PubMed ID: 36308926
[TBL] [Abstract][Full Text] [Related]
2. Deep learning-based predictive model for pathological complete response to neoadjuvant chemotherapy in breast cancer from biopsy pathological images: a multicenter study.
Zeng H; Qiu S; Zhuang S; Wei X; Wu J; Zhang R; Chen K; Wu Z; Zhuang Z
Front Physiol; 2024; 15():1279982. PubMed ID: 38357498
[No Abstract] [Full Text] [Related]
3. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
[TBL] [Abstract][Full Text] [Related]
4. PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
Aswolinskiy W; Munari E; Horlings HM; Mulder L; Bogina G; Sanders J; Liu YH; van den Belt-Dusebout AW; Tessier L; Balkenhol M; Stegeman M; Hoven J; Wesseling J; van der Laak J; Lips EH; Ciompi F
Breast Cancer Res; 2023 Nov; 25(1):142. PubMed ID: 37957667
[TBL] [Abstract][Full Text] [Related]
5. Deep learning-based predictive biomarker of pathological complete response to neoadjuvant chemotherapy from histological images in breast cancer.
Li F; Yang Y; Wei Y; He P; Chen J; Zheng Z; Bu H
J Transl Med; 2021 Aug; 19(1):348. PubMed ID: 34399795
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.
Qu YH; Zhu HT; Cao K; Li XT; Ye M; Sun YS
Thorac Cancer; 2020 Mar; 11(3):651-658. PubMed ID: 31944571
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment ultrasound-based deep learning radiomics model for the early prediction of pathologic response to neoadjuvant chemotherapy in breast cancer.
Yu FH; Miao SM; Li CY; Hang J; Deng J; Ye XH; Liu Y
Eur Radiol; 2023 Aug; 33(8):5634-5644. PubMed ID: 36976336
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
[TBL] [Abstract][Full Text] [Related]
10. Deep learning radiopathomics based on preoperative US images and biopsy whole slide images can distinguish between luminal and non-luminal tumors in early-stage breast cancers.
Huang Y; Yao Z; Li L; Mao R; Huang W; Hu Z; Hu Y; Wang Y; Guo R; Tang X; Yang L; Wang Y; Luo R; Yu J; Zhou J
EBioMedicine; 2023 Aug; 94():104706. PubMed ID: 37478528
[TBL] [Abstract][Full Text] [Related]
11. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
Zhang L; Wang XI; Zhang S
Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
[TBL] [Abstract][Full Text] [Related]
14. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
15. A hierarchical self-attention-guided deep learning framework to predict breast cancer response to chemotherapy using pre-treatment tumor biopsies.
Saednia K; Tran WT; Sadeghi-Naini A
Med Phys; 2023 Dec; 50(12):7852-7864. PubMed ID: 37403567
[TBL] [Abstract][Full Text] [Related]
16. Predicting Neoadjuvant Treatment Response in Triple-Negative Breast Cancer Using Machine Learning.
Bhattarai S; Saini G; Li H; Seth G; Fisher TB; Janssen EAM; Kiraz U; Kong J; Aneja R
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201383
[TBL] [Abstract][Full Text] [Related]
17. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis.
Xia G; Zhang Z; Jiang Q; Wang H; Wang J
Medicine (Baltimore); 2024 Feb; 103(6):e36810. PubMed ID: 38335394
[TBL] [Abstract][Full Text] [Related]
19. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
20. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
